Amicus Therapeutics reports strong revenue growth in 2024, expects further growth in 2025
From GlobeNewswire: 2025-01-12 16:00:00
Amicus Therapeutics reported a total revenue of $528.5 million in 2024, showing a significant 32% year-over-year growth. The company saw strong demand for its Galafold, Pombiliti, and Opfolda treatments, with over 3,000 people treated with Amicus therapy. For 2025, Amicus expects a total revenue growth of 17-24% and plans to focus on expanding its rare disease treatments. Galafold net product sales in 2024 were $458.2 million, while Pombiliti and Opfolda net product sales reached $70.3 million. The company aims to achieve positive GAAP Net Income in the second half of 2025 and surpass $1 billion in total sales by 2028. Galafold, a medication, has common adverse reactions like headache and nausea. Its use in pregnant women is not well-studied, so risks to the fetus are unknown. It’s unclear if Galafold is present in breast milk. The drug is not recommended for patients with severe kidney issues and hasn’t been studied in children. Pombiliti + Opfolda is a two-part therapy for late-onset Pompe disease. It’s indicated for adult patients who aren’t improving on current treatment. Safety information includes warnings about hypersensitivity reactions and fetal harm. Amicus Therapeutics is a biotech company focused on rare diseases. Non-GAAP financial measures are provided for investors and management. Forward-looking statements discuss regulatory approvals and financial projections. Amicus Therapeutics released a statement cautioning investors on potential risks and uncertainties in their business, including regulatory approval delays, manufacturing challenges, and market competition. The company may need additional funding for product manufacturing and commercialization. Actual results may vary from financial guidance and goals due to market factors and operational execution. Forward-looking statements are subject to risks detailed in annual and quarterly reports. Investors are advised not to rely solely on these statements, as they are subject to change. Contact information for investors and media is provided for further inquiries.
Read more at GlobeNewswire: Amicus Therapeutics Reports Preliminary 2024 Revenue and